Primary immune deficiencies: Practical questions

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue SUPPL. 2, 2013, Pages

  Gouilleux Gruart, Valérie ^a   Schleinitz, Nicolas ^b   Fischer, Alain ^c  

^a UNIVERSITÉ DE TOURS   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DEAMINASE; CD18 ANTIGEN; ETOPOSIDE; FC RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2 RECEPTOR GAMMA; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RETROVIRUS VECTOR; STAT1 PROTEIN; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; CELLULAR IMMUNODEFICIENCY; COMMON VARIABLE IMMUNODEFICIENCY; COST EFFECTIVENESS ANALYSIS; CYTOKINE RELEASE; DNA POLYMORPHISM; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; GENE THERAPY; HEALTH CARE COST; HEMOPHAGOCYTIC SYNDROME; HOME CARE; HOSPITAL CARE; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; IMMUNOTHERAPY; INFUSION PUMP; NEWBORN; NONHUMAN; PHAGOCYTE DYSFUNCTION; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE; SEVERE COMBINED IMMUNODEFICIENCY; SIDE EFFECT; SYSTEMIC DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; VARIABLE NUMBER OF TANDEM REPEAT; WISKOTT ALDRICH SYNDROME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; ANTIBODIES, BLOCKING; CYTOKINES; GENETIC THERAPY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; PRACTICE GUIDELINES AS TOPIC; STEM CELL TRANSPLANTATION;

EID: 84880950158     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/01.all.0000433133.93564.c7     Document Type: Article

References (179)

1. Hurez V, Kaveri SV, Kazatchkine MD. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol 1993; 23:783-789.
2. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
3. Durandy A, Kaveri SV, Kuijpers TW, et al. Intravenous immunoglobulins: Understanding properties and mechanisms. Clin Exp Immunol 2009; 158 (Suppl 1):2-13.
4. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 1982; 306:1254-1258.
5. Imbach P, Jungi TW. Possible mechanisms of intravenous immunoglobulin treatment in childhood idiopathic thrombocytopenic purpura (ITP). Blut 1983; 46:117-124.
6. Kazatchkine MD, Dietrich G, Hurez V, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.Ig). Immunol Rev 1994; 139:79-107.
7. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Antiidiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2:765-768.
8. Basta M. Ambivalent effect of immunoglobulins on the complement system: Activation versus inhibition. Mol Immunol 2008; 45:4073-4079.
9. Pashov A, Bellon B, Kaveri SV, Kazatchkine MD. A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg). Mult Scler 1997; 3:153-156.
10. Pashov A, Dubey C, Kaveri SV, et al. Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein. Eur J Immunol 1998; 28:1823-1831.
11. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484-486.
12. Anthony RM, Nimmerjahn F, Ashline DJ, et al. Recapitulation of IVIG antiinflammatory activity with a recombinant IgG Fc. Science 2008; 320:373-376.
13. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475:110-113.
14. Leontyev D, Katsman Y, Ma XZ, et al. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin. Transfusion 2012; 52:1799-1805.
15. Guhr T, Bloem J, Derksen NI, et al. Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia. PLoS One 2011; 6:e21246.
16. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-426.
17. Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010; 11:7-13.
18. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101:758-765.
19. Quartier P, Debre M, De Blic J, et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: A retrospective survey of 31 patients. J Pediatr 1999; 134:589-596.
20. Bayry J, Hermine O, Webster DA, et al. Common variable immunodeficiency: The immune system in chaos. Trends Mol Med 2005; 11:370-376.
21. Bayry J, Lacroix-Desmazes S, Donkova-Petrini V, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci U S A 2004; 101:14210-14215.
22. Bayry J, Lacroix-Desmazes S, Hermine O, et al. Amelioration of differentiation of dendritic cells from CVID patients by intravenous immunoglobulin. Am J Med 2005; 118:1439-1440.
23. Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al. Common variable immunodeficiency is associated with defective functions of dendritic cells. Blood 2004; 104:2441-2443.
24. Bayry J, Fournier EM, Maddur MS, et al. Intravenous immunoglobulin induces proliferation and immunoglobulin synthesis from B cells of patients with common variable immunodeficiency: A mechanism underlying the beneficial effect of IVIg in primary immunodeficiencies. J Autoimmun 2011; 36:9-15.
25. Marketing Research Bureau. The Worldwide Plasma Fractions Market -2008: The Marketing Research Bureau, Inc.; 2010.
26. Robert P. Global plasma demand in 2015. Pharmaceuticals Policy and Law 2009; 11:359-367.
27. Guillevin L. Indications for immunoglobulins. Recommendations of CEDIT of AP-HP in 2006. Rev Med Interne. 2007; 28 (Spec No. 1):1-3. Indications des immunoglobulines. Les recommandations du CEDIT de láP-HP en 2006.
28. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol 2011; 154:76-103.
29. Gajdos P, Tranchant C, Clair B, et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: A randomized double-blind clinical trial. Arch Neurol 2005; 62:1689-1693.
30. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888-898.
31. Zegers BJ, Rijkers GT, Stoop JW. Humoral immunodeficiency: From description to the cellular and molecular basis of the defect. Neth J Med 1991; 39:199-208.
32. The European Agency for the Evaluation of Medicinal Products. Evaluation of Medicines for Human Use. Note for Guidance on the Clinical Investigation of Human Normal Immunoglobulin for Intravenous Administration (IVIg). 2000:CPMP/BPWG/388/95 rev. 1.
33. Azar AE, Ballas ZK. Evaluation of the adult with suspected immunodeficiency. Am J Med 2007; 120:764-768.
34. Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 1978; 62:162-166.
35. Kawano T, Matsuse H, Obase Y, et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol 2002; 128:240-243.
36. Lee RJ, Fay AC. Hypogammaglobulinaemia associated with long term, low dose steroid therapy. Postgrad Med J 1985; 61:523-524.
37. Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol 2006; 97:113-116.
38. Miyakis S, Pefanis A, Passam FH, et al. Thymoma with immunodeficiency (Good's syndrome): Review of the literature apropos three cases. Scand J Infect Dis 2006; 38:314-319.
39. Merino A, de Larrea CF, Blade J. Cytoplasmic inclusions in leukocytes associated to cryoglobulinemia and IgG-kappa monoclonal gammapathy of undetermined significance. Eur J Haematol 2011; 86:550.
40. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23:3412-3420.
41. Karlsson J, Andreasson B, Kondori N, et al. Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom's macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol 2011; 18:969-977.
42. Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982; 96:47-50.
43. Perri RT, Hebbel RP, Oken MM. Influence of treatment and response status on infection risk in multiple myeloma. Am J Med 1981; 71:935-940.
44. Augustson BM, Begum G, Dunn JA, et al. Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002-Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2005; 23:9219-9226.
45. Department of Health. Clinical guidelines for immunoglobulin use. 2nd edition update. Department of Health; 2011. http://www.dh.gov.uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH-129617. [Accessed 5 February 2013].
46. National Blood Authority. Criteria for the clinical use of intravenous immunoglobulin in Australia, 2nd ed. National Blood Authority; 2012. http:// www.nba.gov.au/ivig/index.html. [Accessed 5 February 2013].
47. Robinson P, Anderson D, Brouwers M, et al. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev 2007; 21 (2 Suppl 1):S3-S8.
48. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood 2012; 120:4684-4691.
49. Picard C, Puel A, Bustamante J, et al. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 2003; 3:451-459.
50. Slifka MK, Ahmed R. Long-lived plasma cells: A mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10:252-258.
51. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol 2011; 186:6044-6055.
52. Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103:777-783.
53. Lanini S, Molloy AC, Fine PE, et al. Risk of infection in patients with lymphoma receiving rituximab: Systematic review and meta-analysis. BMC Med 2011; 9:36.
54. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis. Arthritis Rheum 2007; 56:3896-3908.
55. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
56. Svensson M, Dahlin U, Kimby E. Better response with conjugate vaccine than with polysaccaride vaccine 12 months after rituximab treatment in lymphoma patients. Br J Haematol 2012; 156:407-409.
57. Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122:139-145.
58. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: An updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103:1799-1806.
59. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1992; 89:374-377.
60. Blimark C, Mellqvist U-H, Landgren O, et al. Multiple myeloma and infections: A population-based study based on 9610 multiple myeloma patients. Proceedings of the 54th Annual Meeting of the American Society of Hematology (ASH), Atlanta, GA; USA Blood. 2012; 120:Abstract 945.
61. Cheuk DK, Chiang AK, Lee TL, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database Syst Rev. 2011;(3):CD006505.
62. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2007:332-338.
63. Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2008:450-456.
64. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346:564-569.
65. Oken MM, Pomeroy C, Weisdorf D, Bennett JM. Prophylactic antibiotics for the prevention of early infection in multiple myeloma. Am J Med 1996; 100:624-628.
66. Ljungman P, Nahi H, Linde A. Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: A randomised study. Br J Haematol 2005; 130:96-98.
67. Cherif H, Landgren O, Konradsen HB, et al. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. Vaccine 2006; 24:75-81.
68. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: A working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol 2012; 130 (3 Suppl):S1-24.
69. Sinisalo M, Vilpo J, Itala M, et al. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine 2007; 26:82-87.
70. Centers for Disease Control and Prevention. Consensus guidelines for infection prophylaxis including vaccination in multiple myeloma. 13th International Myeloma Workshop, Paris. 2011.
71. Borrow R, Heath PT, Siegrist CA. Use of pneumococcal polysaccharide vaccine in children: What is the evidence? Curr Opin Infect Dis 2012; 25:292-303.
72. Robertson JD, Nagesh K, Jowitt SN, et al. Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma. Br J Cancer 2000; 82:1261-1265.
73. Avci FY, Li X, Tsuji M, Kasper DL. A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design. Nat Med 2011; 17:1602-1609.
74. Baker C, Pickering L, Chilton L, et al. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-64.
75. Raanani P, Gafter-Gvili A, Paul M, et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: Systematic review and meta-analysis. Leuk Lymphoma 2009; 50:764-772.
76. Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet 1994; 343:1059-1063.
77. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med. 1988; 319:902-907.
78. Jurlander J, Geisler CH, Hansen MM. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin. Eur J Haematol 1994; 53:114-118.
79. Chapel H, Dicato M, Gamm H, et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: A comparison of two dose regimes. Br J Haematol 1994; 88:209-212.
80. Sklenar I, Schiffman G, Jonsson V, et al. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology 1993; 50:466-477.
81. Griffiths H, Brennan V, Lea J, et al. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989; 73:366-368.
82. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995; 17: 75-80.
83. Molica S, Musto P, Chiurazzi F, et al. Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996; 81:121-126.
84. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325:81-86.
85. Besa EC, Klumpe D. Prophylactic immune globulin in chronic lymphocytic leukemia. N Engl J Med 1992; 326:139.
86. Mitra A, Fallen RS, Lima HC. Cytokine-based therapy in psoriasis. Clin Rev Allergy Immunol 2012; 44:173-182.
87. van de Veerdonk FL, Lauwerys B, Marijnissen RJ, et al. The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 2011; 63:1507-1516.
88. Scott KA, Moore RJ, Arnott CH, et al. An antitumor necrosis factor-alpha antibody inhibits the development of experimental skin tumors. Mol Cancer Ther 2003; 2:445-451.
89. Askling J, Fahrbach K, Nordstrom B, et al. Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: Meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011; 2:119-130.
90. Mercer LK, Green AC, Galloway JB, et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: Longitudinal results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2012; 71:869-874.
91. Pierard-Franchimont C, Pierard GE, Quatresooz P. Focus on skin cancer association and progression under TNF antagonist therapy. Expert Opin Biol Ther 2011; 11:1215-1222.
92. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345:1098-1104.
93. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun 2001; 69:184-1855.
94. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: Systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295:2275-2285.
95. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-3412.
96. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007; 66:1339-1344.
97. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including sitespecific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:2368-2376.
98. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007; 56:1125-1133.
99. Thompson AE, Rieder SW, Pope JE. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials. Arthritis Rheum 2011; 63:1479-1485.
100. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis 2004; 39:1254-1255.
101. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261-1265.
102. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69:522-528.
103. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with antitumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884-1894.
104. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301:418-426.
105. Mitoma H, Horiuchi T, Tsukamoto H, et al. Mechanisms for cytotoxic effects of antitumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: Comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 2008; 58:1248-1257.
106. Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8R T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. J Clin Invest 2009; 119:1167-1177.
107. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301:737-744.
108. Daridon C, Burmester GR, Dorner T. Anticytokine therapy impacting on B cells in autoimmune diseases. Curr Opin Rheumatol 2009; 21:205-210.
109. Anolik JH, Ravikumar R, Barnard J, et al. Cutting edge: Antitumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. J Immunol 2008; 180:688-692.
110. Platt AM, Gibson VB, Patakas A, et al. Abatacept limits breach of selftolerance in a murine model of arthritis via effects on the generation of T follicular helper cells. J Immunol 2010; 185:1558-1567.
111. Jacobi AM, Huang W, Wang T, et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: Extension of a phase II, doubleblind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010; 62:20-210.
112. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010; 62:2625-2632.
113. Pham T, Fautrel B, Gottenberg JE, et al. Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008; 75 (Suppl 1):S1-99.
114. van Vollenhoven RF, Emery P, Bingham CO, 3rd, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2012. [Epub ahead of print.]
115. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70:909-920.
116. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. Arthritis Rheum 2007; 56:2886-2895.
117. DePry JL, Reed KB, Cook-Norris RH, Brewer JD. Iatrogenic immunosuppression and cutaneous malignancy. Clin Dermatol 2011; 29:602-613.
118. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006; 54:692-701.
119. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann Rheum Dis 2010; 69:400-418.
120. Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: Analysis of the LORHEN registry. Autoimmun Rev 2010; 9:175-180.
121. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: The effect of methotrexate and antitumor necrosis factor therapy in 18 572 patients. Arthritis Rheum 2004; 50:1740-1751.
122. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: A systematic review and meta-analysis. Ann Rheum Dis 2011; 70:1895-1904.
123. Askling J, Baecklund E,Granath F, et al. Antitumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: Relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis 2009; 68:648-653.
124. Wolfe F, Michaud K. The effect of methotrexate and antitumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19 562 patients during 89 710 person-years of observation. Arthritis Rheum 2007; 56: 1433-1439.
125. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: A network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794.
126. Hawryluk EB, Linskey KR, Duncan LM, Nazarian RM. Broad range of adverse cutaneous eruptions in patients on TNF-alpha antagonists. J Cutan Pathol 2012; 39:481-492.
127. Puertas-Abreu E, Polanco ER, Azocar M, et al. Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-alpha. Int Arch Med 2012; 5:7.
128. Wetter DA, Davis MD. Lupus-like syndrome attributable to antitumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84:979-984.
129. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum 2008; 59:996-1001.
130. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007; 143:223-231.
131. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202:135-143.
132. Boyman O, Kovar M, Rubinstein MP, et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311: 1924-1927.
133. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum 2007; 56:2715-2718.
134. Peters MJ, van Sijl AM, Voskuyl AE, et al. The effects of tumor necrosis factor inhibitors on cardiovascular risk in rheumatoid arthritis. Curr Pharm Des 2012; 18:1502-1511.
135. Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: Division into distinct clinical phenotypes. Blood 2008; 112: 277-286.
136. Gouilleux-Gruart V, Chapel H, Chevret S, et al. Efficiency of immunoglobulin G replacement therapy in common variable immunodeficiency: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Clin Exp Immunol 2013; 171:186-194.
137. Oksenhendler E, Chapel H, Gouilleux-Gruart V, et al. Efficiency of IgG replacement therapy in patients with CVID: Correlations with clinical phenotype and polymorphism of the neonatal Fc receptor. Proceeding of the CIS Annual Meeting, 17-20 May, Vevey, Switzerland. 2012.
138. Waldmann TA. Disorders of immunoglobulin metabolism. N Engl J Med 1969; 281:1170-1177.
139. Brambell FW, Hemmings WA, Morris IG. A Theoretical Model of Gamma-Globulin Catabolism. Nature 1964; 203:1352-1354.
140. West AP Jr, Bjorkman PJ. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,). Biochemistry 2000; 39:9698-9708.
141. Vaughn DE, Bjorkman PJ. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor. Structure 1998; 6:63-73.
142. Vidarsson G, Stemerding AM, Stapleton NM, et al. FcRn: An IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108:3573-3579.
143. Liu X, Lu L, Yang Z, et al. The neonatal FcR-mediated presentation of immune-complexed antigen is associated with endosomal and phagosomal pH and antigen stability in macrophages and dendritic cells. J Immunol 2011; 186:4674-4686.
144. Cervenak J, Bender B, Schneider Z, et al. Neonatal FcR overexpression boosts humoral immune response in transgenic mice. J Immunol 2011; 186:959-968.
145. Roopenian DC, Sun VZ. Clinical ramifications of the MHC family Fc receptor FcRn. J Clin Immunol 2010; 30:790-797.
146. Kandil E, Egashira M, Miyoshi O, et al. The human gene encoding the heavy chain of the major histocompatibility complex class I-like Fc receptor (FCGRT) maps to 19q13.3. Cytogenet Cell Genet 1996; 73:97-98.
147. Sachs UJ, Socher I, Braeunlich CG, et al. variable number of tandem repeats polymorphism influences the transcriptional activity of the neonatal Fc receptor alpha-chain promoter. Immunology 2006; 119:83-89.
148. Beaute J, Mahlaoui N, DuDdoit Y, et al. The French national registry of primary immunodeficiency diseases. Clin Immunol 2010; 135:264-272.
149. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: A retrospective analysis. J Clin Immunol 2010; 30:301-307.
150. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000; 20:94-100.
151. Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci 2012; 46:315-321.
152. Vyas GN, Perkins HA, Fudenberg HH. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet 1968; 2:312-315.
153. Rachid R, Bonilla FA. The role of anti-IgA antibodies in causing adverse reactions to gamma globulin infusion in immunodeficient patients: A comprehensive review of the literature. J Allergy Clin Immunol 2012; 129:628-634.
154. Lucas M, Hugh-Jones K, Welby A, et al. Immunomodulatory therapy to achieve maximum efficacy: Doses, monitoring, compliance, and self-infusion at home. J Clin Immunol 2010; 30 (Suppl 1):S84-89.
155. Thepot S, Malphettes M, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: Decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010; 30:602-606.
156. Beaute J, Levy P, Millet V, et al. Economic evaluation of immunoglobulin replacement in patients with primary antibody deficiencies. Clin Exp Immunol 2010; 160:240-245.
157. Misbah S, Sturzenegger MH, Borte M, et al. Subcutaneous immunoglobulin: Opportunities and outlook. Clin Exp Immunol 2009; 158 (Suppl 1):51-59.
158. Marodi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 2007; 7:851-861.
159. Chaffee S, Mary A, Stiehm ER, et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. J Clin Invest 1992; 89:1643-1651.
160. Hanna S, Etzioni A. New host defense mechanisms against Candida species clarify the basis of clinical phenotypes. J Allergy Clin Immunol 2011; 127:1433-1437.
161. Kotlarz D, Beier R, Murugan D, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: Implications for diagnosis and therapy. Gastroenterology 2012; 143:347-355.
162. Brandtzaeg P, Johansen FE. Mucosal B cells: Phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 2005; 206:32-63.
163. Micol R, Kayal S, Mahlaoui N, et al. Protective effect of IgMagainst colonization of the respiratory tract by nontypeable Haemophilus influenzae in patients with hypogammaglobulinemia. J Allergy Clin Immunol 2012; 129:770-777.
164. Donadieu J, Leblanc T, Bader Meunier B, et al. Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 2005; 90:45-53.
165. Wilhelmus KR. Therapeutic interventions for herpes simplex virus epithelial keratitis. Cochrane Database Syst Rev. 2008:CD002898.
166. Qu HQ, Fisher-Hoch SP, McCormick JB. Molecular immunity to mycobacteria: Knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases. Int J Infect Dis 2011; 15:e305-e313.
167. Kuemmerle-Deschner JB, Ramos E, Blank N, et al. Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011; 13:R34.
168. Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010; 62:258-267.
169. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8R T cells and interferon gamma are essential for the disorder. Blood 2004; 104:735-743.
170. Nold-Petry CA, Lehrnbecher T, Jarisch A, et al. Failure of interferon gamma to induce the anti-inflammatory interleukin 18 binding protein in familial hemophagocytosis. PLoS One 2010; 5:e8663.
171. Fujiwara F, Hibi S, Imashuku S. Hypercytokinemia in hemophagocytic syndrome. Am J Pediatr Hematol Oncol 1993; 15:92-98.
172. Billiau AD, Roskams T, Van Damme-Lombaerts R, et al. Macrophage activation syndrome: Characteristic findings on liver biopsy illustrating the key role of activated, IFN-gamma-producing lymphocytes and IL-6-and TNF-alpha-producing macrophages. Blood 2005; 105:1648-1651.
173. Pachlopnik Schmid J, Ho CH, Chretien F, et al. Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27adeficient mice. EMBO Mol Med 2009; 1:112-124.
174. Weitzman S. Approach to hemophagocytic syndromes. Hematology Am Soc Hematol Educ Program 2011; 2011:178-183.
175. Averbuch D, Chapgier A, Boisson-Dupuis S, et al. The clinical spectrum of patients with deficiency of Signal Transducer and Activator of Transcription-1. Pediatr Infect Dis J 2011; 30:352-355.
176. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: Entering a new century, do we do better? J Allergy Clin Immunol 2010; 126:602-610; e1-11.
177. Aiuti A, Cattaneo F, Galimberti S, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009; 360:447-458.
178. Gaspar HB, Cooray S, Gilmour KC, et al. Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 2011; 3:97ra79.
179. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2010; 363:355-364.